glp 1 lipoprotein a The Role of GLP-1RA Medications in Medical Weight Loss and the Positive Impacts on Lipid Management | Current Cardiovascular Risk Reports Mechanisms of GLP-1 Receptor Agonist-Induced
Description
Not for the 60 mg dose (Alli)
A post hoc analysis of the SURMOUNT-5 study found that tirzepatide was associated with a greater predicted 10-year cardiovascular disease risk reduction compared to semaglutide
Average weight loss: 510% over 12 weeks
doi: 10.1111/j.1476-5381.2012.01971.x
The medication is not recommended during pregnancy, breastfeeding, or for people under 18 years of age
